Expression and clinical significance of serum amyloid A and interleukin‑6 in patients with acute exacerbation of chronic obstructive pulmonary disease

Wei,Yongtao; Wang,Songxia; Wang,Dongping; Liu,Cheng

doi:10.3892/etm.2019.8366

Expression and clinical significance of serum amyloid A and interleukin‑6 in patients with acute exacerbation of chronic obstructive pulmonary disease

Authors:
- Yongtao Wei
- Songxia Wang
- Dongping Wang
- Cheng Liu
View Affiliations

Affiliations: Clinical Laboratory, Qingdao Eighth People's Hospital, Qingdao, Shandong 266100, P.R. China, Blood Transfusion Department, Qingdao Eighth People's Hospital, Qingdao, Shandong 266100, P.R. China
Published online on: December 20, 2019 https://doi.org/10.3892/etm.2019.8366
Pages: 2089-2094

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression and clinical significance of serum amyloid A (SAA) and interleukin‑6 (IL‑6) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) were investigated. Fifty‑one patients with AECOPD (acute group, AG) and 51 patients with stable chronic obstructive pulmonary disease (stable group, SG) admitted to Qingdao Eighth People's Hospital were selected. The expression levels of SAA and IL‑6 in peripheral blood of patients in the two groups were detected and compared before and after treatment. Pearson analysis was used in the correlation between SAA and IL‑6 and Receiver operating characteristic (ROC) curve was employd to analyze the predictive value of SAA and IL‑6 for AECOPD progression. Logistic regression analysis was used to analyze the risk factors of AECOPD patients. The expression levels of SAA and IL‑6 of patients in AG were significantly higher than those in SG (P<0.05). Pearson analysis showed that SAA was positively correlated with IL‑6 expression (P<0.05). ROC curve analysis showed that AUC predicted by SAA and IL‑6 for AECOPD progress was 0.789 and 0.762 (P<0.05). Logistic regression analysis showed that SAA and IL‑6 were prediction indexes of AECOPD progression. The levels of SAA and IL‑6 were significantly increased during AECOPD and effectively predicted the progress of AECOPD and is a risk factor affecting AECOPD patients.

View Figures

View References

1	Santibáñez M, Garrastazu R, Ruiz-Nuñez M, Helguera JM, Arenal S, Bonnardeux C, León C and García-Rivero JL: Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease. PLoS One. 11:e01587272016. View Article : Google Scholar : PubMed/NCBI
2	Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, Obeidat M, Henry AP, Portelli MA, Hall RJ, et al Understanding Society Scientific Group; Geisinger-Regeneron DiscovEHR Collaboration, : Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat Genet. 49:416–425. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zhou Y, Zhong NS, Li X, Chen S, Zheng J, Zhao D, Yao W, Zhi R, Wei L, He B, et al: Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 377:923–935. 2017. View Article : Google Scholar : PubMed/NCBI
4	Jinjuvadia C, Jinjuvadia R, Mandapakala C, Durairajan N, Liangpunsakul S and Soubani AO: Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD14. 72–79. 2017. View Article : Google Scholar
5	Cebron Lipovec N, Beijers RJ, van den Borst B, Doehner W, Lainscak M and Schols AM: The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: A systematic review. COPD. 13:399–406. 2016. View Article : Google Scholar : PubMed/NCBI
6	US Preventive Services Task Force (USPSTF), ; Siu AL, Bibbins-Domingo K, Grossman DC, Davidson KW, Epling JW Jr, García FA, Gillman M, Kemper AR, Krist AH, et al: Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA. 315:1372–1377. 2016. View Article : Google Scholar : PubMed/NCBI
7	Tan DBA, Armitage J, Teo TH, Ong NE, Shin H and Moodley YP: Elevated levels of circulating exosome in COPD patients are associated with systemic inflammation. Respir Med. 132:261–264. 2017. View Article : Google Scholar : PubMed/NCBI
8	Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M and Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 60:925–931. 2005. View Article : Google Scholar : PubMed/NCBI
9	Takase H, Tanaka M, Yamamoto A, Watanabe S, Takahashi S, Nadanaka S, Kitagawa H, Yamada T and Mukai T: Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A. Amyloid. 23:67–75. 2016. View Article : Google Scholar : PubMed/NCBI
10	Siegmund SV, Schlosser M, Schildberg FA, Seki E, De Minicis S, Uchinami H, Kuntzen C, Knolle PA, Strassburg CP and Schwabe RF: Serum amyloid a induces inflammation, proliferation and cell death in activated hepatic stellate cells. PLoS One. 11:e01508932016. View Article : Google Scholar : PubMed/NCBI
11	Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW and Cho JY: Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 10:1383–1395. 2011. View Article : Google Scholar : PubMed/NCBI
12	Schaper F and Rose-John S: Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, Ye DW and Tian YK: Interleukin-6: An emerging regulator of pathological pain. J Neuroinflammation. 13:1412016. View Article : Google Scholar : PubMed/NCBI
14	Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B and Vo A: Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation. 101:32–44. 2017. View Article : Google Scholar : PubMed/NCBI
15	Rothaug M, Becker-Pauly C and Rose-John S: The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta 1863A. 1218–1227. 2016. View Article : Google Scholar
16	Lopez-Campos JL, Calero-Acuña C, Lopez-Ramirez C, Abad-Arranz M, Márquez-Martín E, Ortega-Ruiz F and Arellano E: Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease. Biomark Med. 10:109–122. 2016. View Article : Google Scholar : PubMed/NCBI
17	Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Antonio Riesco J, et al: Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 53:324–335. 2017. View Article : Google Scholar : PubMed/NCBI
18	Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 195:557–582. 2017. View Article : Google Scholar : PubMed/NCBI
19	Dalal AA, Christensen L, Liu F and Riedel AA: Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 5:341–349. 2010. View Article : Google Scholar : PubMed/NCBI
20	Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ and Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 157:1418–1422. 1998. View Article : Google Scholar : PubMed/NCBI
21	Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, Criner GJ, Curtis JL, Hanania NA, Nath H, et al COPD Gene Investigators, : Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 195:324–330. 2017.PubMed/NCBI
22	Frame NM and Gursky O: Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. FEBS Lett. 590:866–879. 2016. View Article : Google Scholar : PubMed/NCBI
23	Sack GH Jr: Serum amyloid A - a review. Mol Med. 24:462018. View Article : Google Scholar : PubMed/NCBI
24	De Buck M, Gouwy M, Wang JM, Van Snick J, Opdenakker G, Struyf S and Van Damme J: Structure and expression of different serum amyloid A (SAA) variants and their concentration-dependent functions during host insults. Curr Med Chem. 23:1725–1755. 2016. View Article : Google Scholar : PubMed/NCBI
25	Sun L and Ye RD: Serum amyloid A1: Structure, function and gene polymorphism. Gene. 583:48–57. 2016. View Article : Google Scholar : PubMed/NCBI
26	De Buck M, Gouwy M, Wang JM, Van Snick J, Proost P, Struyf S and Van Damme J: The cytokine-serum amyloid A-chemokine network. Cytokine Growth Factor Rev. 30:55–69. 2016. View Article : Google Scholar : PubMed/NCBI
27	Jensen LE and Whitehead AS: Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J. 334:489–503. 1998. View Article : Google Scholar : PubMed/NCBI
28	Heo TH, Wahler J and Suh N: Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget. 7:15460–15473. 2016. View Article : Google Scholar : PubMed/NCBI
29	Schmidt-Arras D and Rose-John S: IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
30	Jiang Z and Zhu L: Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 37:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
31	Liu X, Jones GW, Choy EH and Jones SA: The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol. 28:152–160. 2016. View Article : Google Scholar : PubMed/NCBI
32	Li W, Zhou Y and Zhang T: Expressions of serum TSLP, SAA, and CRP in COPD patients. J Chin Physician. 20:46–49. 2018.
33	Chen YWR, Leung JM and Sin DD: A systematic review of diagnostic biomarkers of COPD exacerbation. PLoS One. 11:e01588432016. View Article : Google Scholar : PubMed/NCBI
34	Landi A, Broadhurst D, Vernon SD, Tyrrell DL and Houghton M: Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. Cytokine. 78:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
35	Flores RJ: The use of circulating SAA and CXCL4 to predict outcome of osteosarcoma at diagnosis. Cancer Res. 76:4592016.
36	Fu G-Q, Xia J and Wang G: Clinical values of SAA and hs-CRP in the diagnosis of postoperative infection in patients with ovarian tumor. Zhongguo Jiceng Yiyao. 24:1069–1072. 2017.(In Chinese).